Health100 is designed as a cross-stakeholder digital destination, avoiding closed proprietary architectures to connect ...
In today’s Pharma Pulse, Antengene and UCB ink a $1.18 billion global deal for ATG-201 to target autoimmune diseases, while ...
Esperion Therapeutics has entered into a definitive agreement to acquire Corstasis Therapeutics, a privately held biopharmaceutical company. The acquisition focuses on the integration of Enbumyst™ ...
The FDA has transitioned to a "new era" of proactive enforcement, issuing warning letters to telehealth and pharmaceutical companies to eliminate misleading promotional claims and ensure a fair ...
Eton Pharmaceuticals. Eton Pharmaceuticals expands rare disease portfolio through acquisition of U.S. commercialization rights to HEMANGEOL® (propranolol hydrochloride) oral solution. Eton ...
In today's Pharma Pulse, the FDA expands the pediatric indication for Juxtapid to treat rare homozygous familial hypercholesterolemia, while Novo Nordisk announces a major €432 million investment in ...
SpotSee and Controlant announced a collaboration to enhance pharmaceutical supply chain visibility using integrated ...
Thermal testing can make or break cold chain performance. Join this webinar to learn proven best practices that help eliminate blind spots, validate designs, and protect temperature-sensitive ...
A conversation with Kenco’s Tim McClatchy explores how pharmaceutical logistics providers are strengthening cybersecurity ...
The Inflation Reduction Act (IRA) of 2022 introduced sweeping changes to the US prescription drug market, most notably empowering Medicare to negotiate prices on high-cost medications, capping ...
In today’s Pharma Pulse, the FDA grants priority review to a therapy for polycythemia vera, while Novo Nordisk receives expanded pediatric approval for its once-weekly growth hormone.
Global life sciences supply chain conference LogiPharma has announced a brand-new series of interactive formats for 2026 under the leadership of incoming event director, Ben Sharples.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results